Vaughan Nelson Investment Management L.P. Has $22.55 Million Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Vaughan Nelson Investment Management L.P. raised its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 9.9% during the 4th quarter, Holdings Channel reports. The institutional investor owned 361,615 shares of the company’s stock after acquiring an additional 32,605 shares during the quarter. Vaughan Nelson Investment Management L.P.’s holdings in TransMedics Group were worth $22,547,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TMDX. Wilmington Savings Fund Society FSB raised its stake in shares of TransMedics Group by 68.5% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 1,601 shares of the company’s stock worth $100,000 after purchasing an additional 651 shares in the last quarter. State of Alaska Department of Revenue increased its holdings in TransMedics Group by 17.0% during the fourth quarter. State of Alaska Department of Revenue now owns 19,074 shares of the company’s stock worth $1,189,000 after buying an additional 2,766 shares during the last quarter. Hager Investment Management Services LLC bought a new stake in TransMedics Group during the fourth quarter worth $33,000. Yousif Capital Management LLC lifted its stake in TransMedics Group by 14.6% in the fourth quarter. Yousif Capital Management LLC now owns 12,954 shares of the company’s stock valued at $808,000 after acquiring an additional 1,652 shares during the last quarter. Finally, Guidance Capital Inc. grew its position in shares of TransMedics Group by 54.5% in the 4th quarter. Guidance Capital Inc. now owns 3,642 shares of the company’s stock valued at $222,000 after acquiring an additional 1,284 shares during the period. 99.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Robert W. Baird dropped their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Piper Sandler dropped their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. TD Cowen cut their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Oppenheimer reissued an “outperform” rating and set a $125.00 target price on shares of TransMedics Group in a report on Tuesday, December 3rd. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $122.70.

Insiders Place Their Bets

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the transaction, the insider now owns 20,843 shares in the company, valued at $1,800,835.20. This trade represents a 4.94 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Stock Down 1.2 %

TMDX opened at $72.60 on Monday. The stock has a fifty day moving average of $66.11 and a 200-day moving average of $109.31. The company has a market capitalization of $2.44 billion, a P/E ratio of 77.23 and a beta of 2.12. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.